Part I. FINANCIAL INFORMATION This section provides the company's financial statements, management's analysis, market risk disclosures, and internal controls [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited consolidated financial statements for Selecta Biosciences, Inc. as of September 30, 2020, and for the three and nine months then ended. It includes the Consolidated Balance Sheets, Statements of Operations, Statements of Changes in Stockholders' Equity, and Statements of Cash Flows, accompanied by detailed Notes to the Financial Statements which elaborate on accounting policies and significant transactions, including new collaboration agreements and financing activities [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) Presents the company's financial position, including assets, liabilities, and equity, at specific points in time Consolidated Balance Sheet Highlights (in thousands) | Balance Sheet Item | Sep 30, 2020 (Unaudited) | Dec 31, 2019 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $146,261 | $89,893 | | Total current assets | $166,502 | $96,667 | | Total assets | $180,996 | $99,569 | | **Liabilities & Equity** | | | | Total current liabilities | $77,004 | $34,943 | | Total liabilities | $188,378 | $91,172 | | Total stockholders' (deficit) equity | $(7,382) | $8,397 | | Total liabilities and stockholders' (deficit) equity | $180,996 | $99,569 | [Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Details the company's revenues, expenses, and net loss over specific periods Statement of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended Sep 30, 2020 | Three Months Ended Sep 30, 2019 | Nine Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2019 | | :--- | :--- | :--- | :--- | :--- | | Grant and collaboration revenue | $4,646 | $0 | $4,646 | $23 | | Research and development | $13,960 | $8,104 | $39,414 | $27,591 | | General and administrative | $4,420 | $3,690 | $14,155 | $12,317 | | Loss from operations | $(13,734) | $(11,794) | $(48,923) | $(39,885) | | Net loss | $(9,729) | $(11,994) | $(53,430) | $(40,462) | | Net loss per share (basic and diluted) | $(0.09) | $(0.26) | $(0.54) | $(0.94) | [Consolidated Statements of Cash Flows](index=8&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Summarizes the cash inflows and outflows from operating, investing, and financing activities Cash Flow Summary (in thousands) | Cash Flow Activity | Nine Months Ended Sep 30, 2020 | Nine Months Ended Sep 30, 2019 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $42,131 | $(38,559) | | Net cash (used in) provided by investing activities | $(575) | $238 | | Net cash provided by financing activities | $14,621 | $36,507 | | Net change in cash, cash equivalents, and restricted cash | $56,089 | $(1,790) | | Cash, cash equivalents, and restricted cash at end of period | $147,640 | $35,892 | [Notes to Consolidated Financial Statements (Unaudited)](index=10&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements%20(Unaudited)) The notes provide detailed explanations of the company's accounting policies and financial activities. Key disclosures include the nature of the business as a clinical-stage biotech focused on the ImmTOR™ platform, liquidity status with cash runway into Q1 2023, details of significant collaboration and revenue agreements with Sobi, Sarepta, and AskBio, information on debt facilities including a new $35M term loan, and equity financing activities such as private placements and at-the-market offerings - The company is a clinical-stage biotechnology company leveraging its ImmTOR™ platform to amplify the efficacy of biologics and restore self-tolerance in autoimmune diseases[31](index=31&type=chunk) - As of September 30, 2020, the company's cash, cash equivalents, and restricted cash of **$147.6 million** are expected to fund operations into the first quarter of 2023[39](index=39&type=chunk) - In August 2020, the company entered into a new term loan agreement for up to **$35.0 million**, drawing down an initial **$25.0 million** (Term A Loan)[106](index=106&type=chunk) - In June 2020, the company entered into a significant license and development agreement with Sobi for SEL-212, receiving a **$75 million** upfront payment and a **$25 million** equity investment. Sobi will also reimburse costs for the Phase 3 DISSOLVE trials[169](index=169&type=chunk)[172](index=172&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=42&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's strategic focus on its ImmTOR™ platform, particularly for gene therapy and autoimmune diseases, following the licensing of its lead candidate, SEL-212, to Sobi. The analysis covers financial results for the third quarter and first nine months of 2020, highlighting a significant increase in revenue from the Sobi agreement and a rise in R&D expenses due to the initiation of the Phase 3 DISSOLVE program. The company confirms its cash runway extends into Q1 2023, supported by recent financing and collaboration payments [Overview](index=42&type=section&id=Overview) The company is a clinical-stage biopharmaceutical firm focused on its ImmTOR™ immune tolerance platform. Its strategy is to amplify biologic efficacy (e.g., enabling gene therapy re-dosing) and restore self-tolerance in autoimmune diseases. The lead candidate, SEL-212 for chronic refractory gout, was licensed to Sobi in June 2020, with Phase 3 trials initiated in September 2020. The pipeline also includes programs in IgA nephropathy, gene therapies for MMA (with AskBio) and OTC deficiency, and an autoimmune program in PBC - Strategic focus is on the ImmTOR platform to amplify biologic efficacy and restore self-tolerance in autoimmune diseases[247](index=247&type=chunk)[248](index=248&type=chunk) - Lead product candidate SEL-212 for chronic refractory gout was licensed to Sobi in June 2020. The Phase 3 DISSOLVE clinical program, funded by Sobi, commenced in September 2020[248](index=248&type=chunk)[252](index=252&type=chunk) - The pipeline includes gene therapy programs in collaboration with AskBio for methylmalonic acidemia (MMA) and a proprietary program for OTC deficiency, as well as an autoimmune program for primary biliary cholangitis (PBC)[255](index=255&type=chunk)[256](index=256&type=chunk)[257](index=257&type=chunk) [Results of Operations](index=48&type=section&id=Results%20of%20Operations) For the third quarter of 2020, revenue was $4.6 million, primarily from the Sobi and Sarepta agreements, compared to zero in Q3 2019. R&D expenses increased 72% to $14.0 million due to the Phase 3 DISSOLVE program initiation. G&A expenses rose 20% to $4.4 million. For the nine months ended September 30, 2020, revenue was also $4.6 million, R&D expenses increased 43% to $39.4 million, and G&A expenses increased 15% to $14.2 million. The net loss for the nine months was $53.4 million, up from $40.5 million in the prior year period Comparison of Results for the Three Months Ended September 30 (in thousands) | Metric | 2020 | 2019 | Change | Change % | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $4,646 | $0 | $4,646 | N/A | | Research & Development | $13,960 | $8,104 | $5,856 | 72% | | General & Administrative | $4,420 | $3,690 | $730 | 20% | Comparison of Results for the Nine Months Ended September 30 (in thousands) | Metric | 2020 | 2019 | Change | Change % | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $4,646 | $23 | $4,623 | 201% | | Research & Development | $39,414 | $27,591 | $11,823 | 43% | | General & Administrative | $14,155 | $12,317 | $1,838 | 15% | - A gain of **$4.8 million** was recognized in Q3 2020 from the decrease in fair value of warrant liabilities, while a loss of **$3.6 million** was recognized for the nine-month period due to an increase in fair value[295](index=295&type=chunk)[305](index=305&type=chunk) [Liquidity and Capital Resources](index=50&type=section&id=Liquidity%20and%20Capital%20Resources) As of September 30, 2020, the company had $147.6 million in cash, cash equivalents, and restricted cash. Management believes these funds are sufficient to support operations into the first quarter of 2023. This position was strengthened by a $75 million upfront payment from Sobi, a $25 million equity investment from Sobi, and a new $35 million debt facility, of which $25 million was drawn. The company continues to utilize its "at-the-market" offering for additional funding - The company believes its existing cash of **$147.6 million** as of September 30, 2020, will fund operating expenses and capital expenditure requirements into the first quarter of 2023[328](index=328&type=chunk)[272](index=272&type=chunk) - In June 2020, the company entered into the Sobi License agreement, receiving **$75 million** upfront and a **$25 million** equity investment. Sobi will also fund the Phase 3 clinical program for SEL-212[312](index=312&type=chunk) - In August 2020, the company secured a new term loan facility for up to **$35.0 million** and drew down the initial **$25.0 million** tranche[319](index=319&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=57&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk exposure is to interest rate changes affecting its cash, cash equivalents, and investments. However, due to the short-term and low-risk nature of these holdings, management believes a 100 basis point change in interest rates would not have a material effect. The company also has minor foreign currency risk from its Russian subsidiary, which held $0.3 million in U.S. dollars as of September 30, 2020 - The primary market risk is interest rate sensitivity on cash and investments, which is considered not to have a material effect on fair market value[354](index=354&type=chunk) - The company is subject to foreign currency risk from its Russian subsidiary, which held cash of **$0.3 million** as of September 30, 2020[355](index=355&type=chunk) [Controls and Procedures](index=58&type=section&id=Item%204.%20Controls%20and%20Procedures) Based on an evaluation as of September 30, 2020, the company's management, including the CEO and CFO, concluded that its disclosure controls and procedures were effective at a reasonable assurance level. There were no material changes in internal control over financial reporting during the third quarter of 2020 - Management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of September 30, 2020[357](index=357&type=chunk) - No changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, internal controls were identified during Q3 2020[358](index=358&type=chunk) Part II. OTHER INFORMATION This section covers legal proceedings, detailed risk factors, and other miscellaneous disclosures required for the report [Legal Proceedings](index=59&type=section&id=Item%201.%20Legal%20Proceedings) The company discloses a shareholder derivative action filed on August 3, 2020, in the Court of Chancery of the State of Delaware. The complaint alleges that certain current and former directors breached their fiduciary duties in connection with a private placement transaction announced in December 2019. The defendants filed a motion to dismiss on September 25, 2020 - A shareholder derivative action was filed on August 3, 2020, against certain current and former directors, alleging breach of fiduciary duties related to a December 2019 private placement[361](index=361&type=chunk) [Risk Factors](index=59&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks that could materially affect the company's business. Key risks include its history of losses and need for additional capital; reliance on the unproven ImmTOR platform; uncertainties in clinical development and regulatory approval; dependence on third parties like 3SBio for manufacturing and Sobi for commercialization; potential for product liability and competition; challenges in protecting intellectual property; and operational risks related to its new strategy and retaining key personnel [Risks Related to Financial Position and Need for Additional Capital](index=59&type=section&id=Risks%20Related%20to%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) Highlights risks associated with the company's financial health, including historical losses and future funding requirements - The company is a development-stage company with a history of significant losses (**$389.2 million** accumulated deficit as of Sep 30, 2020) and expects to incur losses for the foreseeable future[363](index=363&type=chunk) - Substantial additional funding will be needed to complete development and commercialization of product candidates. Failure to raise capital could force delays or elimination of programs[368](index=368&type=chunk) [Risks Related to Discovery, Development and Regulatory Approval](index=62&type=section&id=Risks%20Related%20to%20Discovery%2C%20Development%20and%20Regulatory%20Approval) Addresses the inherent uncertainties and challenges in the clinical development and regulatory approval process for product candidates - The company's product candidates are based on the ImmTOR platform, which is an unproven approach, and the company is in the early stages of most clinical development efforts[380](index=380&type=chunk) - Clinical drug development is a lengthy, expensive process with an uncertain outcome. The company may incur additional costs or delays and could ultimately be unable to complete development[394](index=394&type=chunk) - The COVID-19 pandemic may continue to adversely impact business, including preclinical studies and clinical trials, through delays in enrollment, site initiation, and supply chain disruptions[406](index=406&type=chunk) [Risks Related to Dependence on Third Parties and Manufacturing](index=74&type=section&id=Risks%20Related%20to%20Dependence%20on%20Third%20Parties%20and%20Manufacturing) Discusses risks arising from reliance on external partners for manufacturing, supply, and collaboration agreements - The company relies on 3SBio in China as the primary supplier of pegadricase, a key component of SEL-212, exposing it to supply disruption, geopolitical, and tariff risks[430](index=430&type=chunk)[431](index=431&type=chunk)[432](index=432&type=chunk) - Reliance on third-party contract manufacturers for all product candidates increases risks related to supply quantity, cost, quality, and regulatory compliance (cGMP)[435](index=435&type=chunk)[437](index=437&type=chunk) - Existing collaborations (e.g., Sobi, AskBio) are important to the business, and the failure to maintain these or enter new ones could adversely affect development and funding[439](index=439&type=chunk) [Risks Related to Commercialization and Legal Compliance](index=78&type=section&id=Risks%20Related%20to%20Commercialization%20and%20Legal%20Compliance) Covers challenges in achieving market acceptance, building sales infrastructure, and adhering to complex healthcare regulations - Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, and payors[451](index=451&type=chunk) - The company has no sales organization and will need to build one or rely on third parties, which carries significant risks and costs[452](index=452&type=chunk) - The business is subject to complex healthcare laws, including anti-kickback and fraud statutes, which could expose it to criminal sanctions and civil penalties[470](index=470&type=chunk) [Risks Related to Intellectual Property](index=88&type=section&id=Risks%20Related%20to%20Intellectual%20Property) Outlines risks concerning the protection, maintenance, and potential infringement of the company's intellectual property rights - The company's success depends on its ability to obtain and maintain patent protection for its technology and products, which is an expensive and uncertain process[495](index=495&type=chunk) - The company may be subject to litigation alleging infringement of third-party intellectual property rights, which could be costly and disruptive[512](index=512&type=chunk) - Failure to comply with obligations in intellectual property license agreements could result in the loss of important rights to the company's product candidates[522](index=522&type=chunk) [Risks Related to Operations and Common Stock](index=94&type=section&id=Risks%20Related%20to%20Operations%20and%20Common%20Stock) Examines operational challenges, dependence on key personnel, and factors affecting the volatility of the company's stock price - The company's new corporate strategy focusing on the ImmTOR platform post-Sobi deal may not be successful[533](index=533&type=chunk) - Future success is highly dependent on retaining key executives, like the CEO, and attracting qualified personnel in a competitive market[536](index=536&type=chunk) - The market price of the company's common stock is likely to be volatile and could fluctuate substantially[549](index=549&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=100&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds for the period covered by this report - None reported [Defaults Upon Senior Securities](index=100&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None reported [Mine Safety Disclosures](index=100&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable [Other Information](index=100&type=section&id=Item%205.%20Other%20Information) The company reported no other information for this period - None reported [Exhibits](index=101&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q. Notable exhibits include the company's restated certificate of incorporation and bylaws, warrant forms, the amended Registration Rights Agreement with Sobi, a new employment agreement, the new Loan and Security Agreement with Oxford Finance and SVB, and officer certifications - Key exhibits filed include the Loan and Security Agreement dated August 31, 2020, and the amended Registration Rights Agreement with Sobi[571](index=571&type=chunk)

O Selecta… Biosciences Corporate Presentation September 2020 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and pegloticase and related data readouts, the potential of ImmTOR™ to reduce AAV vector immunogenicity and enab ...

O श्रे Selecta. Biosciences Corporate Presentation August 2020 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and pegloticase and related data readouts, the potential of ImmTOR™ to reduce AAV vector immunogenicity and en ...

Financial Data and Key Metrics Changes - As of June 30, 2020, the company had $61.4 million in cash, cash equivalents, and restricted cash, down from $91.6 million as of December 31, 2019 [24] - Net cash used in operating activities was $23.5 million for the first half of 2020, compared to $27.4 million for the same period in 2019 [25] - The company reported a net loss of $24.1 million or $0.25 per share for the second quarter of 2020, compared to a net loss of $16.4 million or $0.37 per share for the same period in 2019 [26] Business Line Data and Key Metrics Changes - Research and development expenses for Q2 2020 were $10.7 million, down from $12.1 million in Q2 2019, primarily due to reduced expenses for the Phase II COMPARE trial for SEL-212 [25] - General and administrative expenses increased to $5.6 million in Q2 2020 from $4.1 million in Q2 2019, attributed to higher salaries and legal fees [26] Market Data and Key Metrics Changes - The strategic licensing agreement with Sobi, which closed on July 28, 2020, allows Sobi to assume responsibility for all development, regulatory, and commercial activities in all markets except China [9][11] - The company anticipates the initiation of the Phase III clinical program for SEL-212 in Q3 2020, consisting of two double-blinded placebo-controlled trials [12] Company Strategy and Development Direction - The company aims to maximize the potential of the ImmTOR immune tolerance platform, focusing on optimizing the efficacy and safety of biologics and enabling redosing of gene therapies [9][10] - The company has entered into a research license agreement with Sarepta for the use of ImmTOR in neuromuscular diseases, particularly Duchenne muscular dystrophy [15] - The lead gene therapy program in methylmalonic acidemia (MMA) is expected to enter the clinic in the first half of 2021, with preliminary data anticipated in the second half of 2021 [16] Management's Comments on Operating Environment and Future Outlook - Management described Q2 2020 as a transformational time for the company, emphasizing the importance of strategic business decisions made during this period [8] - The management expressed confidence in the company's ability to advance its clinical programs and capitalize on business development opportunities [27] Other Important Information - The company plans to host an R&D Day in October to provide specific details on gene therapy and autoimmune disease programs [27] - The newly appointed Chief Medical Officer, Dr. Peter G. Traber, brings extensive experience and will oversee medical affairs and clinical development [19] Q&A Session Summary Question: What are the gating factors before entering the clinic for MMA? - The company is finalizing toxicology studies and preparing for the IND filing, on track to start the trial in the first half of next year [30] Question: How will the dosing schedule be determined for the OTC deficiency program? - The company will use learnings from the MMA program for dose finding and aims to prevent the formation of neutralizing antibodies as a proof of concept [34][36] Question: What specific antigens are being targeted for IgA nephropathy? - The approach will involve combining ImmTOR with an IgA protease to address IgA immune complex deposits in the kidney [39] Question: How does the ImmTOR platform translate across different serotypes? - The technology is believed to be agnostic to serotypes, with applications for next-generation capsids [44] Question: What are the economic terms of the AskBio partnership? - The partnership includes a classical licensing deal with upfront payments and milestone payments, as well as a 50-50 cost and profit-sharing collaboration for the MMA program [67]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (State or other jurisdiction of incorporation or organization) (I. ...

SEL-212 for Chronic Refractory Gout - SEL-212 addresses a $1B+ chronic refractory gout market with high unmet need[5,15] - In a Phase 2 dose ranging study, 66% (21/32) of patients achieved SUA levels <6 mg/dL after 20 weeks of once-monthly SEL-212 treatment[17,18] - The company is conducting a head-to-head trial (COMPARE) of SEL-212 against pegloticase in chronic refractory gout patients, with approximately 150 patients enrolled[5,32] - Top-line data from the COMPARE trial is expected in 3Q 2020, and a Phase 3 pivotal program against placebo is planned for 2H 2020[5,64] ImmTOR Platform in Gene Therapy - The company's ImmTOR platform aims to mitigate Neutralizing Antibody (Nab) formation, potentially enabling re-dosing of AAV gene therapies[5] - Preclinical studies suggest ImmTOR can induce antigen-specific immune tolerance, preventing NAb development in mice treated with ImmTOR+AAV vector[42] - A license agreement with AskBio includes upfront payments of $7 million and potential clinical and sales milestone payments of $237 million for Pompe disease[50] - The company expects to commence a human POC trial under the AskBio collaboration in 4Q 2020[64] Financial Status - As of March 31, 2020, the company had $74.264 million in cash, cash equivalents, marketable securities, and restricted cash[61]

Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Elona Kogan - General Counsel & Corporate Secretary Bradford Dahms - CFO, Principal Financial Officer & Principal Accounting Officer Carsten Brunn - CEO, President & Director Kei Kishimoto - Chief Scientific Officer Conference Call Participants Ellie Merle - Cantor Fitzgerald & Co. Raju Prasad - William Blair & Company Yun Zhong - Janney Montgomery Scott John Newman - Canaccord Genuity Difei Yang - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer Identification No.) (State or other jurisdiction ...

O ato Selecta.. Biosciences Corporate Presentation April 2 0 2 0 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delawar | | --- | Delaware 26-1622110 (I.R.S. Employer ...